NDA 021272 · United Therap
Remodulin
Treprostinil · Intravenous, Subcutaneous · Prostacycline Vasodilator
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
May 21, 2002
Approved uses
3
Original approval plus efficacy supplements
Registered trials
129
42 Phase 3, 15 recruiting
FAERS reports
65,346
41,979 serious, 9,061 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2026.
Remodulin is a prostacyclin mimetic indicated for: Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 ) 1.1 Pulmonary Arterial Hypertension Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1) ] . 1.2 Pulmonary Arterial Hypertension in Patients Requiring Transition from Epoprostenol In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.
Mechanism: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 20, 2006 Supplement 5 · Efficacy · priority review LabelReviewLetter
- Nov 24, 2004 Supplement 2 · Efficacy Review
- May 21, 2002 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
8 products under this application
- REMODULIN · TREPROSTINIL 0.2MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
- REMODULIN · TREPROSTINIL 20MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
- REMODULIN · TREPROSTINIL 5MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
- REMODULIN · TREPROSTINIL 1MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
- REMODULIN · TREPROSTINIL 0.4MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription
- REMODULIN · TREPROSTINIL 0.1MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
- REMODULIN · TREPROSTINIL 10MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
- REMODULIN · TREPROSTINIL 2.5MG/ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseasePivotal-lookingEnrolling by invitation
United TherapeuticsIndustry
NCT04905693 · 1,850 participants (planned) · Start Sep 6, 2022 · Primary completion Dec 2029
Drug: Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Franklin, Arizona; Phoenix, Arizona · 192 sites in all
- An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01027949 · 894 participants · Start Jan 16, 2007 · Primary completion Feb 12, 2020
Drug: Oral Treprostinil · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 134 sites in all
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07805785 · 800 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 31, 2030
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: DuBois, Pennsylvania
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Pivotal-lookingRecruiting
United TherapeuticsIndustry
NCT05943535 · 698 participants (planned) · Start Oct 30, 2023 · Primary completion Nov 2027
Drug: Placebo; Inhaled Treprostinil · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 165 sites in all
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01560624 · 690 participants · Start Jun 26, 2012 · Primary completion Jun 24, 2018
Drug: Treprostinil Diolamine; Placebo · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 155 sites in all
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT04708782 · 598 participants · Start Jun 1, 2021 · Primary completion Feb 2, 2026
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 98 sites in all
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT05255991 · 597 participants · Start Sep 12, 2022 · Primary completion Jun 30, 2025
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Mar del Plata, Argentina; Córdoba, Argentina · 108 sites in all
- An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01560637 · 471 participants · Start Sep 11, 2013 · Primary completion Aug 12, 2021
Drug: UT-15C (treprostinil diolamine) · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 153 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea9,904
- headache7,178
- diarrhoea6,904
- nausea6,212
- infusion site pain5,788
- death5,236
- fatigue4,101
- dizziness3,852
- vomiting3,407
- infusion site erythema3,353
- pain in extremity2,976
- hypotension2,834
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 35 |
| 2005 | 62 |
| 2006 | 88 |
| 2007 | 43 |
| 2008 | 36 |
| 2009 | 71 |
| 2010 | 900 |
| 2011 | 1,625 |
| 2012 | 657 |
| 2013 | 1,002 |
| 2014 | 4,603 |
| 2015 | 5,481 |
| 2016 | 4,840 |
| 2017 | 4,855 |
| 2018 | 5,311 |
| 2019 | 4,970 |
| 2020 | 4,272 |
| 2021 | 4,041 |
| 2022 | 4,380 |
| 2023 | 5,081 |
| 2024 | 4,633 |
| 2025 | 4,928 |
| 2026 | 3,432 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Remodulin (Treprostinil Sodium)
2024 spending
$13.5M
Beneficiaries
110
1,228 claims
Per beneficiary
$122,999
$437.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,233,310 |
| 2021 | $6,905,569 |
| 2022 | $10,337,855 |
| 2023 | $11,819,879 |
| 2024 | $13,529,903 |
Part B: Remodulin* (Treprostinil Sodium*) · HCPCS J3285
2024 spending
$122M
Beneficiaries
909
12,831 claims
Per beneficiary
$133,774
2024 ASP limit $55.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $163,468,435 |
| 2021 | $155,903,548 |
| 2022 | $130,449,989 |
| 2023 | $126,521,237 |
| 2024 | $121,601,006 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Nathan SD, Smith P, Deng C, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Nathan SD, Smith P, Deng C, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results.
Nathan SD, Argula R, Trivieri MG, et al. · Eur Respir J 2024 · Randomized Controlled Trial, Multicenter Study
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. · Eur Respir J 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Nathan SD, Waxman A, Rajagopal S, et al. · Lancet Respir Med 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: United Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.